HealthDay News — For pediatric-onset treatment-resistant epilepsy, cannabinoids are effective as an adjunctive treatment for reducing seizure frequency by 50% or more, according to a review published online in the Journal of Neurology, Neurosurgery Psychiatry.
Emily Stockings, PhD, from the National Drug and Alcohol Research Centre in Sydney, and colleagues reviewed the evidence for cannabinoids as adjunctive treatments for treatment-resistant epilepsy. Data were included from 6 randomized controlled trials and 30 observational studies. The outcomes of interest were 50% or more seizure reduction, complete seizure freedom, and improved quality of life.
The researchers found that, compared with placebo, cannabidiol (CBD) 20 mg/kg/day was more effective for reducing seizure frequency by 50% or more (relative risk, 1.74). For one person using CBD to experience a 50% or greater seizure reduction, the number needed to treat was eight. CBD was also more effective than placebo for achieving complete seizure freedom and